HER-2 Positive Breast Cancer Market in the US 2015-2019

HER-2 Positive Breast Cancer Market in the US 2015-2019

About HER-2 Positive Breast Cancer

Breast cancer is characterized by uncontrolled growth of cancerous cells in the breast. It occurs in both males and females, however, the incidence of breast cancer in males is rare. Histologically, breast cancer can be classified into ductal carcinoma, lobular carcinoma, nipple cancer, and other undifferentiated carcinoma. Breast cancer is the second most common form of cancer in women. HER-2 is a protein that affects the growth of malignant cells and is usually found on the surface of normal breast cells. Sometimes, a large number of HER-2 receptors are found on the surface of breast cancer cells. These HER-2 receptors are responsible for stimulating the growth and division of malignant cancerous cells. This condition is therefore known as HER-2 positive breast cancer. HER-2 positive breast cancers have a tendency to spread and metastasize more rapidly than HER-2 negative breast cancers. HER-2 positive breast cancer is more prevalent in females than males. In 2012, GLOBOCAN reported that breast cancer accounted for 11.9 percent of the total number of cancer cases and led to 522,000 deaths worldwide. HER-2 positive breast cancer accounts for almost 25 percent of all types of breast cancer.

TechNavio's analysts forecast the HER-2 Positive Breast Cancer market in US to grow at a CAGR of 12.65 percent over the period 2014-2019.

Covered in this Report

This report covers the present scenario and the growth prospects of the HER-2 Positive Breast Cancer market in the US for the period 2015-2019. To calculate the market size, the report considers revenue generated through the sales of targeted therapeutics and chemotherapeutics used in the management of HER-2 positive breast cancer patients. The report also presents the vendor landscape and a corresponding detailed analysis of the top vendors in the HER-2 Positive Breast Cancer market in the US. In addition, it discusses the major drivers that influence the growth of the market. It also outlines the challenges faced by the vendors and the market at large, as well as the key trends that are emerging in the market.

TechNavio's report, HER-2 Positive Breast Cancer Market in US 2015-2019, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape of the HER-2 Positive Breast Cancer market in the US and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

Key Vendors

• Celgene
• F. Hoffmann-La Roche
• GlaxoSmithKline
• Novartis
• Sanofi

Other Prominent Vendors

• Bristol-Myers Squibb
• DARA BioSciences
• Eisai
• Hospira
• Pfizer
• ProStrakan
• Sun Pharmaceutical Industries
• Teva Pharmaceutical
Market Driver
• Increase in Population of Breast Cancer Patients
• For a full, detailed list, view our report
Market Challenge
• Poor Diagnosis and Screening
• For a full, detailed list, view our report
Market Trend
• Increase in Awareness
• For a full, detailed list, view our report

Key Questions Answered in this Report

• What will the market size be in 2019 and what will the growth rate be?
• What are the key market trends?
• What is driving this market?
• What are the challenges to market growth?
• Who are the key vendors in this market space?
• What are the market opportunities and threats faced by the key vendors?
• What are the strengths and weaknesses of the key vendors?

Press Release

TechNavio Announces the Publication of its Research Report – HER-2 Positive Breast Cancer Market in the US 2015-2019

TechNavio recognizes the following companies as the key players in the HER-2 Positive Breast Cancer Market in the US: Celgene Corp., F. Hoffmann-La Roche Ltd., GlaxoSmithKline plc, Novartis AG and Sanofi SA

Other Prominent Vendors in the market are: Bristol-Myers Squibb, DARA BioSciences, Eisai, Hospira, Pfizer, ProStrakan, Sun Pharmaceutical Industries and Teva Pharmaceutical.

Commenting on the report, an analyst from TechNavio’s team said: “One key trend upcoming in this market is the increase in awareness. Awareness and screening programs can help diagnose potential breast cancer cases, which might otherwise remain undetected till the last stage.”

According to the report, the increase in prevalence of breast cancer is one of the major contributors to the growth of the market. A sedentary lifestyle coupled with increased urbanization and increased life expectancy raises the chance of developing diseases such as breast cancer.

Further, the report states that a primary challenge faced by this market is the poor diagnosis and screening rate for breast cancer. Diagnosis at a later stage limits the effectiveness of a treatment, despite its availability.

Companies Mentioned

Celgene, F. Hoffmann-La Roche, GlaxoSmithKline, Novartis, Sanofi, Bristol-Myers Squibb , DARA BioSciences, Eisai , Hospira , Pfizer , ProStrakan, Sun Pharmaceutical Industries , Teva Pharmaceutical